Physician profile
David Bryan George
NPI 1376525212
$4,138.38
in general payments reported to CMS, 2019-2025
38 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $409 · 2021: $577 · 2022: $746 · 2023: $481 · 2024: $581 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,667.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $618.87 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $405.81 | 2019-2024 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $379.67 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.32 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $185.34 | 2019-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.65 | 2020-2025 | Xifaxan |
| Abbott Laboratories | $170.53 | 2021-2022 | |
| Astellas Pharma US INC | $159.56 | 2019-2024 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $158.24 | 2023-2025 | Accrufer |
| Glaxosmithkline, LLC. | $155.43 | 2019-2023 | Arexvy, Shingrix |
| Mylan Specialty L.P. | $114.98 | 2022-2024 | Yupelri |
| Amarin Pharma, INC. | $111.72 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $109.09 | 2019-2025 | |
| Abbvie INC. | $101.84 | 2022-2025 | |
| Allergan, INC. | $94.88 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.